Piramal Pharma invests $90m in US sites for sterile injectables and ADC therapies

From Yahoo Finance: 2025-07-01 07:33:00

Piramal Pharma Solutions invests $90m to expand US facilities for sterile injectables and ADC therapies. Ground-breaking ceremony held in Lexington for site expansion. Riverview, Michigan site to be operational by end of 2025, enhancing capabilities for HPAPIs and ADC therapies under ADCelerate program. Lexington site to increase fill/finish facility by late 2027, boosting production capacity.

CEO Peter DeYoung highlights ADCs as effective precision immunotherapy for cancers. Expansions aim to meet growing demand for ADC therapies. Market growth for sterile injectables drives investment. ADC therapies gain traction for efficacy. Lexington site expansion creates 40 permanent positions.

Investment at Piramal Pharma sites to enhance integrated ADC offering and increase capacity. Expansion targets increased medical needs, regulatory approvals, and scientific progress. Lexington and Riverview facilities to accommodate demand. ADC therapies gaining wider acceptance among healthcare regulators. Expansion to conclude by late 2027, increasing production capacity significantly.

Read more: Piramal Pharma announces $90m investment to expand US sites